Adult Clinical Trials

Genitourinary Cancers - Prostate cancer and cancers of the kidney, bladder, and male organs

25 trials identified.

Whole Blood from Healthy Volunteers for the Study of Circulating Tumor Cells
Phase: Phase II
Sponsor: PI initiated
Principal Investigator: Andrew Armstrong
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00027680

Evaluation of lymph node metastases in men undergoing treatment with sipuleucel-T for metastatic castrate-resistant prostate cancer
Phase: Phase I
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Brant Inman
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.9822
Reference Number: 00047231

A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects with Castration-Resistant Prostate Cancer
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Daniel George
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00048629
View this trial at ClinicalTrials.gov

Molecular mechanisms underlying prostate cancer disparities.
Phase: N/A
Sponsor: Internal Investigator Initiated Non-therapeutic/Non-interventional
Principal Investigator: Steven Patierno
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00053535

EXTEND: Safety and Efficacy of EXercise Training in Men Receiving ENzalutamide in Combination with Conventional Androgen Deprivation Therapy for Hormone Nave Prostate Cancer
Phase: Phase II
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Michael Harrison
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00053924
View this trial at ClinicalTrials.gov

PEAX: Men with Metastatic Castrate-Resistant Prostate Cancer Treated with Either Sipuleucel-T (Provenge), Enzalutamide (Xtandi) or Abiraterone Acetate (Zytiga) Undergoing Cardiopulmonary EXercise Testing
Phase: N/A
Sponsor: Internal Investigator Initiated Non-therapeutic/Non-interventional
Principal Investigator: Michael Harrison
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00058229
View this trial at ClinicalTrials.gov

Feasibility of a consumer based accelerometer in monitoring outpatient physical activity: A study in patients with Cancer and Amyotrophic Lateral Sclerosis.
Phase: N/A
Sponsor: Internal Investigator Initiated Non-therapeutic/Non-interventional
Principal Investigator: Michael Harrison
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00063108

Defining the Relevant Immune Checkpoints Expressed on Metastatic Prostate Cancer Circulating Tumor Cells
Phase: N/A
Sponsor: Internal Investigator Initiated Non-therapeutic/Non-interventional
Principal Investigator: Andrew Armstrong
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00063296

PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) VS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE Urothelial Carcinoma AFTER Surgical Resection
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Brant Inman
Contact: UROLOGY CLINICAL RESEARCH OFFICE
Phone: 919.681.3675
Reference Number: 00063661
View this trial at ClinicalTrials.gov

A Randomized Phase 2 Study of Sipuleucel-T with or without Radium-223 in Men with Asymptomatic or Minimally Symptomatic Bone-Metastatic Castrate-Resistant Prostate Cancer
Phase: Phase II
Sponsor: External Investigator-Sponsored (External Med Ctr)
Principal Investigator: Andrew Armstrong
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00065532
View this trial at ClinicalTrials.gov

A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Subjects with Metastatic Castrate-Resistant Prostate Cancer
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Andrew Armstrong
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00066478
View this trial at ClinicalTrials.gov

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of a Vaccine-Based Immunotherapy Regimen (VBIR) for Prostate Cancer (Pf-06753512)
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Tian Zhang
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00067872
View this trial at ClinicalTrials.gov

A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men with Biopsy Proven Low-Grade Prostate Cancer who are Candidates for Active Surveillance (proSPECT-AS)
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Thomas Polascik
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00069229

A Phase Ib study of intravenous copper loading with oral disulfiram in metastatic, castration resistant prostate cancer
Phase: Phase I
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Tian Zhang
Contact: GU Oncology Research Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00071007
View this trial at ClinicalTrials.gov

A Phase Ib, Open-Label Study of the Safety and Tolerability of Atezolizumab in Combination with Radium-223 Dichloride in Patients with Castrate-Resistant Prostate Cancer Who Have Progressed Following Treatment With An Androgen Pathway Inhibitor
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Andrew Armstrong
Contact: GU Oncology Clinical Trials Research Office
Phone: 919.681.1030
Reference Number: 00072263
View this trial at ClinicalTrials.gov

Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing
Phase: Phase II
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Michael Harrison
Contact: GU Oncology Research Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00072588

A Multinational, Phase 3, Randomized, Double-blind, Placebo- controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Andrew Armstrong
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00073953
View this trial at ClinicalTrials.gov

SWOG S1500 A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib, Crizotinib, Savolitinib, and Sunitinib) in Metastatic Papillary Renal Carcinoma (PAPMET)
Phase: Phase II
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: GU Oncology Clinical Trials Research Office
Phone: 919.668.8108
Reference Number: 00074249
View this trial at ClinicalTrials.gov

A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Tian Zhang
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00074533
View this trial at ClinicalTrials.gov

Prospective study of Apalutamide and Abiraterone Acetate in Chemotherapy-Nave men with mCRPC Stratified by Race
Phase: Phase II
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Daniel George
Contact: GU Oncology Research Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00075097
View this trial at ClinicalTrials.gov

Exploring relevant immune-based biomarkers and circulating tumor cells during treatment with immune checkpoint inhibitors in genitourinary malignancies
Phase: N/A
Sponsor: Internal Investigator Initiated Non-therapeutic/Non-interventional
Principal Investigator: Tian Zhang
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00076768

INJECT: A pilot study of intra-tumoral injections in metastatic prostate cancer
Phase: N/A
Sponsor: Internal Investigator Initiated Non-therapeutic/Non-interventional
Principal Investigator: Daniel George
Contact: GU Oncology Research Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00078508

Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN)
Phase: N/A
Sponsor: External Investigator-Sponsored (External Med Ctr)
Principal Investigator: Tian Zhang
Contact: GU Oncology Research Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00080554
View this trial at ClinicalTrials.gov

Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: 0073103 EIRB
Contact: GU Oncology Research Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00081276
View this trial at ClinicalTrials.gov

Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) model of Genitourinary (GU) Cancers
Phase: N/A
Sponsor: Internal Investigator Initiated Non-therapeutic/Non-interventional
Principal Investigator: Shiaowen Hsu
Contact: GU Oncology Research Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00082398
View this trial at ClinicalTrials.gov